Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Gastrointestinal 2Head & Neck 1Dermatologic 1Breast 1

Conditions

Colorectal Neoplasms 187Carcinoma, Non-Small-Cell Lung 85Breast Neoplasms 66Neoplasms 62Ovarian Neoplasms 59Glioblastoma 40Carcinoma, Hepatocellular 36Neoplasm Metastasis 32Colonic Neoplasms 27Carcinoma, Renal Cell 24Fallopian Tube Neoplasms 23Uterine Cervical Neoplasms 21Rectal Neoplasms 17Pancreatic Neoplasms 17Lung Neoplasms 17Stomach Neoplasms 15Liver Neoplasms 15Brain Neoplasms 14Non-Squamous Non-Small Cell Lung Cancer 13Endometrial Neoplasms 11Recurrence 10Glioma 10Carcinoma, Ovarian Epithelial 10Triple Negative Breast Neoplasms 9Melanoma 9Gastrointestinal Neoplasms 9Advanced Solid Tumors 9Solid Cancers 7Peritoneal Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7

Interventions

pembrolizumab 40Gemcitabine 37Cisplatin 28Carboplatin 17enfortumab vedotin 15Nivolumab 15Mitomycin 14atezolizumab 13avelumab 12Docetaxel 10vinflunine 95-aminolevulinic acid hexyl ester 9apaziquone 8Paclitaxel 8BCG Vaccine 7durvalumab 6Fluorouracil 6Cystectomy 6sacituzumab govitecan 4Surgical Procedures, Operative 4Drug Therapy 4vofatamab 3valrubicin 3tisotumab vedotin 3erdafitinib 3cemiplimab 3belinostat 3Therapeutic Uses 3Ramucirumab 3Cystoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Urinary Bladder Neoplasms × Bevacizumab × Clear all
NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡